- Home
- TKLF vs BIVI Comparison
TKLF vs BIVI Comparison
Compare TKLF & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- BIVI
- Stock Information
- Founded
- TKLF 2006
- BIVI 2013
- Country
- TKLF Japan
- BIVI United States
- Employees
- TKLF N/A
- BIVI N/A
- Industry
- TKLF Other Specialty Stores
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- BIVI Health Care
- Exchange
- TKLF Nasdaq
- BIVI Nasdaq
- Market Cap
- TKLF 16.0M
- BIVI 18.6M
- IPO Year
- TKLF 2022
- BIVI N/A
- Fundamental
- Price
- TKLF $3.56
- BIVI $1.02
- Analyst Decision
- TKLF
- BIVI Strong Buy
- Analyst Count
- TKLF 0
- BIVI 1
- Target Price
- TKLF N/A
- BIVI $30.00
- AVG Volume (30 Days)
- TKLF 10.6K
- BIVI 194.8K
- Earning Date
- TKLF 07-15-2025
- BIVI 05-12-2025
- Dividend Yield
- TKLF N/A
- BIVI N/A
- EPS Growth
- TKLF N/A
- BIVI N/A
- EPS
- TKLF 1.70
- BIVI N/A
- Revenue
- TKLF $219,520,631.00
- BIVI N/A
- Revenue This Year
- TKLF N/A
- BIVI N/A
- Revenue Next Year
- TKLF N/A
- BIVI N/A
- P/E Ratio
- TKLF $2.18
- BIVI N/A
- Revenue Growth
- TKLF 32.02
- BIVI N/A
- 52 Week Low
- TKLF $2.20
- BIVI $0.62
- 52 Week High
- TKLF $8.53
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- TKLF 51.46
- BIVI 47.95
- Support Level
- TKLF $3.20
- BIVI $1.00
- Resistance Level
- TKLF $3.85
- BIVI $1.09
- Average True Range (ATR)
- TKLF 0.20
- BIVI 0.07
- MACD
- TKLF -0.02
- BIVI -0.01
- Stochastic Oscillator
- TKLF 60.93
- BIVI 19.05
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.